Marc Uemura

1.2k total citations
20 papers, 662 citations indexed

About

Marc Uemura is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Marc Uemura has authored 20 papers receiving a total of 662 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 4 papers in Molecular Biology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Marc Uemura's work include Cancer Immunotherapy and Biomarkers (9 papers), CAR-T cell therapy research (4 papers) and Hepatocellular Carcinoma Treatment and Prognosis (3 papers). Marc Uemura is often cited by papers focused on Cancer Immunotherapy and Biomarkers (9 papers), CAR-T cell therapy research (4 papers) and Hepatocellular Carcinoma Treatment and Prognosis (3 papers). Marc Uemura collaborates with scholars based in United States, Australia and Italy. Marc Uemura's co-authors include Adi Diab, Van Anh Trinh, Patrick Hwu, Daniel H. Johnson, J. Yeh, Michael T. Tetzlaff, Jonathan L. Curry, Jean Tayar, María E. Suarez‐Almazor and Natalie Jackson and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Marc Uemura

19 papers receiving 653 citations

Peers

Marc Uemura

ONCOL

IMMUN

GENET

PRM

Scott L. Townley Australia

Sabrina Bossio Italy

Maxim Kebenko Germany

Maja Ludvigsen Denmark

Rama Jasty United States

Margaret H. Veldman-Jones United Kingdom

Sabine Claßen Germany

Aurélie Tormo Canada

Emilie Laprévotte France

Phyllis Harbor United States

Scott L. Townley Australia

Marc Uemura

161 ×0.4

ONCOL

233 ×1.1

IMMUN

296 ×1.6

26 ×0.4

GENET

92 ×1.6

PRM

Citations per year, relative to Marc Uemura Marc Uemura (= 1×) peers Scott L. Townley

Countries citing papers authored by Marc Uemura

Since Specialization

Citations

This map shows the geographic impact of Marc Uemura's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marc Uemura with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marc Uemura more than expected).

Fields of papers citing papers by Marc Uemura

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marc Uemura. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marc Uemura. The network helps show where Marc Uemura may publish in the future.

Co-authorship network of co-authors of Marc Uemura

This figure shows the co-authorship network connecting the top 25 collaborators of Marc Uemura. A scholar is included among the top collaborators of Marc Uemura based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marc Uemura. Marc Uemura is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gutierrez, Martin, Georgina V. Long, Claire F. Friedman, et al.. (2020). Anti-CTLA-4 probody BMS-986249 alone or in combination with nivolumab in patients with advanced cancers: Initial phase I results.. Journal of Clinical Oncology. 38(15_suppl). 3058–3058. 7 indexed citations

Johnson, Daniel H., Anisha B. Patel, Marc Uemura, et al.. (2019). IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy. Cancer Immunology Research. 7(6). 860–865. 91 indexed citations

Uemura, Marc, Kenneth R. Hess, Diane Liu, et al.. (2018). Development of CNS metastases and survival in patients with inflammatory breast cancer. Cancer. 124(11). 2299–2305. 11 indexed citations

Diab, Adi, Cara Haymaker, Marc Uemura, et al.. (2017). A Phase 1/2 trial of intratumoral (i.t.) IMO-2125 (IMO) in combination with checkpoint inhibitors (CPI) in PD-(L)1-refractory melanoma. Annals of Oncology. 28. v421–v421. 11 indexed citations

Uemura, Marc, Wei Qiao, Keith F. Fournier, et al.. (2017). Retrospective study of nonmucinous appendiceal adenocarcinomas: role of systemic chemotherapy and cytoreductive surgery. BMC Cancer. 17(1). 331–331. 10 indexed citations

Laçin, Şahin, Reham Abdel‐Wahab, Marc Uemura, et al.. (2017). Nonalcoholic steatohepatitis-related hepatocellular carcinoma: is there a role for the androgen receptor pathway?. OncoTargets and Therapy. Volume 10. 1403–1412. 6 indexed citations

Kim, Sang Taek, Jean Tayar, Van Anh Trinh, et al.. (2017). Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series. Annals of the Rheumatic Diseases. 76(12). 2061–2064. 127 indexed citations

Haymaker, Cara, Dae Won Kim, Marc Uemura, et al.. (2017). Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade. Cancer Immunology Research. 5(2). 100–105. 41 indexed citations

Kim, Sung Tae, et al.. (2017). FRI0604 Successful treatment of arthritis induced by checkpoint inhibitors with anti–interleukin-6 receptor antibody: a case series. Annals of the Rheumatic Diseases. 76. 717–718. 1 indexed citations

10.

Uemura, Marc, Cara Haymaker, Ravi Murthy, et al.. (2017). Intratumoral (i.t.) IMO-2125 (IMO), a TLR9 agonist, in combination with ipilimumab (ipi) in PD-(L)1 refractory melanoma (RM).. Journal of Clinical Oncology. 35(7_suppl). 136–136. 2 indexed citations

11.

Kim, Dae Won, Marc Uemura, & Adi Diab. (2017). Comprehensive Review of PD1/L1 Inhibition in Metastatic Solid Tumors: Safety, fficacy and Resistance. 6(2). 1 indexed citations

12.

Jazaeri, Amir A., Carlos A. Torres‐Cabala, Brinda Rao Korivi, et al.. (2017). Erythema nodosum‐like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy—Report of 2 patients. Journal of Cutaneous Pathology. 44(12). 1080–1086. 43 indexed citations

13.

Uemura, Marc, Van Anh Trinh, Cara Haymaker, et al.. (2016). Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn’s disease: a case report. Journal of Hematology & Oncology. 9(1). 81–81. 54 indexed citations

14.

Uemura, Marc, Faisal Fa’ak, Cara Haymaker, et al.. (2016). A case report of Grover’s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1. Journal for ImmunoTherapy of Cancer. 4(1). 55–55. 38 indexed citations

15.

Uemura, Marc, Wei Qiao, Keith F. Fournier, et al.. (2016). Retrospective study of non-mucinous appendiceal adenocarcinomas: Role of systemic chemotherapy and cytoreductive surgery.. Journal of Clinical Oncology. 34(4_suppl). 263–263. 1 indexed citations

16.

Uemura, Marc, Ahmed O. Kaseb, Reham Abdel‐Wahab, et al.. (2015). Hepatitis B- and C-associated hepatocellular carcinoma in a large U.S. cancer center: Do clinicopathologic features or patient outcomes differ by the potentially causative viruses?. Journal of Clinical Oncology. 33(15_suppl). 4011–4011.

17.

Uemura, Marc, et al.. (2013). Hemophagocytic Lymphohistiocytosis Complicating T-Cell Lymphoma in a Patient with HIV Infection. SHILAP Revista de lepidopterología. 2013. 1–4. 7 indexed citations

18.

Uemura, Marc, et al.. (2013). Enhancing Quality Improvements in Cancer Care Through CME Activities at a Nationally Recognized Cancer Center. Journal of Cancer Education. 28(2). 215–220. 6 indexed citations

19.

Yeh, J. & Marc Uemura. (2012). Hepatocellular Carcinoma. New England Journal of Medicine. 366(1). 92–93. 38 indexed citations

20.

Matheu, Melanie P., Christine Beeton, Adriana Garcia, et al.. (2008). Imaging of Effector Memory T Cells during a Delayed-Type Hypersensitivity Reaction and Suppression by Kv1.3 Channel Block. Immunity. 29(4). 602–614. 167 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact